KalVista Pharmaceuticals Highlights Results from the P-III (KONFIDENT) Study of Sebetralstat for Hereditary Angioedema
Shots:
- KalVista reported results from the P-III (KONFIDENT) study assessing the efficacy and safety of sebetralstat (300mg & 600mg) vs PBO for treating patients (n=136) with HAE. The company anticipates NDA submission to the US FDA in H1’24
- The results demonstrated that HAE attacks treated with sebetralstat attained faster onset of symptom relief with a median time of 1.61hrs. for 300mg, 1.79hrs. for 600mg & 6.72hrs. for PBO. Both the doses also reduced attack severity quickly from baseline & showed a complete attack resolution faster vs PBO
- The safety profile was consistent & well-tolerated without treatment-related SAEs & withdrawals due to AEs. TRAE rates were 2.3% for 300mg & 2.2% for 600mg sebetralstat vs 4.8% for PBO
Ref: KalVista Pharmaceuticals | Image: KalVista Pharmaceuticals
Related News:- Ionis Reports Data from the P-III (OASIS-HAE) Trial of Donidalorsen for the Treatment of Hereditary Angioedema
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
